Stock listing
gettex:C68 Crescent Biopharma, Inc. Aktie
German listing (gettex) of Crescent Biopharma, Inc. · home listing NASDAQ:CBIO
Follow Crescent Biopharma, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CBIO
$13.00 USD +0.60 (+4.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CBIO
- Day range
- $12.53 – $13.30 USDNov 20, 2026
- Volume
- 422,370 sharesNov 20, 2026
- Market cap
- $482.9M USDAt the close on Nov 20, 2026 · price × 37.14M shares outstanding
- 52-week range
- $8.72 – $27.41 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $5.56M USDMedian day 264,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CBIO · Home | $13.00 USD | +0.60 (+4.8%) | 422,370 | $12.55 | $13.30 | $12.53 | $12.40 | Close on Nov 20, 2026 |
| Frankfurt:C68 | €11.00 EUR | +0.40 (+3.8%) | — | €11.00 | €11.00 | €11.00 | €10.60 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CBIO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $13.00 | +0.60 | +4.8% | $12.55 | $13.30 | $12.53 | 422,370 | |
| $12.40 | -0.64 | -4.9% | $13.07 | $13.62 | $12.29 | 327,265 | |
| $13.04 | -0.46 | -3.4% | $13.44 | $13.50 | $12.85 | 214,585 | |
| $13.50 | -0.65 | -4.6% | $14.09 | $14.42 | $12.95 | 417,072 | |
| $14.15 | -0.22 | -1.5% | $15.21 | $15.21 | $13.53 | 284,754 | |
| $14.37 | -0.385 | -2.6% | $14.51 | $15.44 | $14.16 | 209,892 | |
| $14.76 | +0.835 | +6.0% | $14.04 | $15.00 | $13.86 | 269,517 | |
| $13.92 | +0.27 | +2.0% | $13.51 | $14.05 | $13.27 | 168,277 | |
| $13.65 | +0.11 | +0.8% | $13.77 | $14.48 | $13.56 | 206,110 | |
| $13.54 | +0.60 | +4.6% | $12.84 | $13.91 | $12.78 | 137,757 | |
| $12.94 | -0.88 | -6.4% | $13.77 | $13.77 | $12.72 | 191,582 | |
| $13.82 | +0.76 | +5.8% | $13.43 | $14.01 | $13.17 | 172,845 | |
| $13.06 | +0.15 | +1.2% | $12.91 | $13.64 | $12.91 | 159,531 | |
| $12.91 | -0.57 | -4.2% | $13.75 | $13.92 | $12.68 | 147,307 | |
| $13.48 | -0.59 | -4.2% | $13.94 | $14.57 | $13.31 | 189,518 | |
| $14.07 | +0.57 | +4.2% | $13.66 | $14.94 | $13.56 | 378,000 | |
| $13.50 | +0.23 | +1.7% | $13.27 | $13.64 | $12.75 | 238,700 | |
| $13.27 | +0.51 | +4.0% | $12.81 | $13.47 | $12.56 | 288,200 | |
| $12.76 | -0.06 | -0.5% | $12.87 | $13.27 | $12.50 | 210,600 | |
| $12.82 | -0.32 | -2.4% | $13.36 | $13.36 | $12.62 | 397,800 | |
| $13.14 | -0.03 | -0.2% | $13.05 | $13.67 | $12.89 | 164,100 | |
| $13.17 | +0.10 | +0.8% | $13.16 | $13.81 | $13.12 | 250,400 | |
| $13.07 | +0.71 | +5.7% | $12.40 | $13.63 | $12.40 | 299,600 | |
| $12.36 | +0.52 | +4.4% | $11.91 | $12.94 | $11.82 | 230,700 | |
| $11.84 | -0.64 | -5.1% | $12.73 | $12.73 | $11.78 | 208,200 | |
| $12.48 | -0.10 | -0.8% | $12.62 | $13.19 | $12.31 | 295,900 | |
| $12.58 | -0.33 | -2.6% | $12.67 | $13.21 | $12.18 | 284,800 | |
| $12.91 | -1.55 | -10.7% | $14.46 | $14.67 | $12.85 | 197,100 | |
| $14.46 | -0.45 | -3.0% | $14.79 | $15.09 | $14.32 | 153,900 | |
| $14.91 | +0.79 | +5.6% | $14.07 | $15.28 | $14.07 | 347,100 | |
| $14.12 | +0.63 | +4.7% | $13.39 | $14.61 | $12.98 | 301,200 | |
| $13.49 | -0.08 | -0.6% | $13.47 | $14.20 | $13.27 | 1,049,300 | |
| $13.57 | -0.37 | -2.7% | $14.78 | $14.93 | $13.46 | 492,400 | |
| $13.94 | -0.38 | -2.7% | $14.42 | $14.42 | $13.63 | 187,000 | |
| $14.32 | +0.06 | +0.4% | $14.48 | $14.55 | $14.07 | 283,300 | |
| $14.26 | -0.33 | -2.3% | $14.61 | $14.73 | $14.10 | 300,900 | |
| $14.59 | -0.17 | -1.2% | $14.89 | $15.00 | $14.23 | 289,500 | |
| $14.76 | +0.23 | +1.6% | $14.66 | $15.62 | $14.16 | 684,600 | |
| $14.53 | +0.54 | +3.9% | $13.93 | $14.76 | $13.50 | 290,900 | |
| $13.99 | -0.25 | -1.8% | $14.29 | $14.46 | $13.66 | 228,700 | |
| $14.24 | +0.05 | +0.4% | $14.04 | $14.48 | $13.44 | 568,800 | |
| $14.19 | -2.25 | -13.7% | $16.37 | $16.47 | $13.70 | 727,700 | |
| $16.44 | +0.19 | +1.2% | $16.48 | $16.65 | $16.01 | 257,600 | |
| $16.25 | -0.64 | -3.8% | $16.93 | $17.04 | $15.76 | 375,800 | |
| $16.89 | +0.12 | +0.7% | $16.67 | $17.87 | $16.15 | 3,123,500 | |
| $16.77 | -0.41 | -2.4% | $17.60 | $18.57 | $16.32 | 665,900 | |
| $17.18 | -1.62 | -8.6% | $18.87 | $19.26 | $17.09 | 528,900 | |
| $18.80 | -0.88 | -4.5% | $19.60 | $20.31 | $18.40 | 358,000 | |
| $19.68 | +0.27 | +1.4% | $19.50 | $20.40 | $19.40 | 251,200 | |
| $19.41 | -0.05 | -0.3% | $19.81 | $20.35 | $19.11 | 264,400 | |
| $19.46 | -0.53 | -2.7% | $19.65 | $19.90 | $19.16 | 233,100 | |
| $19.99 | -0.47 | -2.3% | $20.30 | $20.91 | $19.92 | 296,000 | |
| $20.46 | -0.42 | -2.0% | $20.58 | $21.19 | $19.91 | 646,700 | |
| $20.88 | +0.48 | +2.4% | $20.09 | $21.53 | $20.09 | 239,700 | |
| $20.40 | +1.86 | +10.0% | $18.73 | $22.33 | $18.73 | 773,300 | |
| $18.54 | +0.61 | +3.4% | $18.00 | $19.01 | $17.93 | 214,900 | |
| $17.93 | +1.33 | +8.0% | $16.43 | $18.13 | $16.29 | 788,100 | |
| $16.60 | -1.15 | -6.5% | $17.65 | $17.65 | $16.14 | 163,000 | |
| $17.75 | -0.01 | -0.1% | $17.78 | $18.00 | $17.02 | 149,100 | |
| $17.76 | -0.26 | -1.4% | $17.89 | $18.26 | $17.50 | 76,700 | |
| $18.02 | +1.02 | +6.0% | $16.94 | $18.47 | $16.94 | 317,600 | |
| $17.00 | +0.03 | +0.2% | $17.12 | $17.66 | $16.87 | 129,700 | |
| $16.97 | -0.18 | -1.0% | $17.21 | $17.51 | $16.79 | 131,500 | |
| $17.15 | +0.92 | +5.7% | $16.39 | $17.19 | $16.03 | 218,400 | |
| $16.23 | -1.09 | -6.3% | $17.13 | $17.13 | $16.06 | 124,800 |
Splits
1 split · NASDAQ:CBIO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-100 | Consolidation |
- Ticker
- gettex:C68
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 56 slides
Latest news
Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Nov 12, 2026
Closed $14.15 (-1.5%) on Nov 13, 2026
Crescent Biopharma Announces Grants of Inducement Awards
Nov 3, 2026
Closed $13.82 (+5.8%) on Nov 4, 2026
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
Oct 15, 2026
Closed $11.84 (-5.1%) on Oct 16, 2026
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
Oct 5, 2026
Closed $13.94 (-2.7%) on Oct 5, 2026
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Jul 30, 2026
Closed $15.02 (+1.7%) on Jul 30, 2026
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jul 16, 2026
Closed $14.75 (-2.4%) on Jul 17, 2026
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Jul 14, 2026
Closed $15.67 (+2.4%) on Jul 15, 2026
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Jul 14, 2026
Closed $15.67 (+2.4%) on Jul 15, 2026
Crescent Biopharma to Present at June Investor Conferences
Jun 2, 2026
Closed $17.98 (+5.7%) on Jun 3, 2026
Crescent Biopharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 21 in the last 12 months · 27 in all · newest Nov 12, 2026 · oldest 2025
- Calls
- 13 calls with a replay · 13 with a transcript · latest May 9, 2024
- Decks
- 7 decks · latest October 2026
Where Crescent Biopharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CBIO · Home listing | NASDAQ | United States | USD |
| Lang & Schwarz:A41BDZ | Lang & Schwarz | Germany | EUR |
| BOATS:CBIO | BOATS | United States | USD |
| Frankfurt:C68 | Frankfurt | Germany | EUR |
| gettex:C68 · This page | gettex | Germany | EUR |
Valuation
EV/sales 13.1× against a median of 12.5×: 3rd lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $196.0M USD
- P/E
- Loss
- EV/sales
- 13.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.8×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- −727.6%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.92
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Crescent Biopharma, Inc. · NASDAQ:CBIO | US$482.9M | US$196.0M | n/a | 13.1× | n/a | 1.8× | −727.6% | 0.0× | 0.92 |
| Wave Life Sciences Ltd. · NASDAQ:WVE | US$504.9M | US$74.16M | n/a | 1.1× | n/a | 1.3× | −296.9% | 0.0× | 1.70 |
| Adlai Nortye Group Ltd. · NASDAQ:ANL | US$502.2M | US$297.0M | n/a | 59.4× | n/a | 2.3× | −710.6% | 0.1× | 1.96 |
| Steminent Biotherapeutics, Inc. · TPEX:7729 | US$496.9M | US$470.4M | n/a | n/a | n/a | 16.2× | n/a | 0.0× | n/a |
| Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575 | US$495.2M | US$407.1M | n/a | 23.2× | n/a | 2.2× | −200.8% | 0.0× | n/a |
| TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872 | US$489.2M | US$391.6M | n/a | n/a | n/a | 5.0× | n/a | 0.1× | n/a |
| Sana Biotechnology, Inc. · NASDAQ:SANA | US$476.4M | US$408.5M | n/a | n/a | n/a | 2.6× | n/a | 0.3× | 2.29 |
| Regenxbio Inc. · NASDAQ:RGNX | US$473.4M | US$289.0M | n/a | 1.9× | n/a | 3.2× | −113.9% | 0.5× | 1.60 |
| Monopar Therapeutics Inc. · NASDAQ:MNPR | US$467.6M | US$362.8M | n/a | n/a | n/a | 3.7× | n/a | 0.0× | 1.18 |
| BlossomHill Therapeutics, Inc. · NASDAQ:BLSM | US$461.2M | US$259.4M | n/a | n/a | n/a | 2.2× | n/a | 0.1× | n/a |
| Neurogene Inc. · NASDAQ:NGNE | US$458.5M | US$106.4M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.47 |
| Median of the others | US$482.8M | US$329.9M | 12.5× | 2.5× | −248.8% | 0.1× | 1.65 |
Forecasts
7 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 31.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.35 · 3 analysts
- Revenue, year to Dec 2026
- 1.73M · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Joshua Brumm | Chief Executive Officer |
| Rick Scalzo | Chief Financial Officer |
| Ryan Lynch | Senior Vice President, Finance and Chief Accounting Officer |
| Jonathan McNeill | President and Chief Operating Officer |
| Barbara Bispham | General Counsel |
| Jenna Poist | Director, Corporate Communications |
| Tanya Sengupta | Executive Vice President, Chief of Strategy and Operations |
| Wenjie Cheng | Senior Vice President, Technical Operations |
| Amy Reilly | Chief Communications Officer |
| Chris Doughty | Chief Business Officer |
| Ellie Im | Chief Medical Officer |
| Jan Pinkas | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Peter Harwin | Chair of Board |
| David Lubner | Director |
| Jonathan Violin | Director |
| Joshua Brumm | Chief Executive Officer |
| Susan Moran | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| GlycoMimetics, Inc. (GLYC) Q1 2024 Earnings Call | Thu, May 09, 2024 · 8:30 AM ET | Replay |
| GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call | Wed, Mar 27, 2024 · 8:30 AM ET | Replay |
| GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call | Fri, Nov 03, 2023 · 8:30 AM ET | Replay |
| GlycoMimetics, Inc. (GLYC) Q2 2023 Earnings Call | Wed, Aug 02, 2023 · 8:30 AM ET | Replay |
| GlycoMimetics, Inc. (GLYC) Q1 2023 Earnings Call | Wed, May 03, 2023 · 8:30 AM ET | Replay |
| GlycoMimetics, Inc. (GLYC) Q4 2022 Earnings Call | Wed, Mar 29, 2023 · 8:30 AM ET | Replay |
| GlycoMimetics, Inc. (GLYC) Q3 2022 Earnings Call | Wed, Nov 09, 2022 · 8:30 AM ET | Replay |
| GlycoMimetics, Inc. (GLYC) Q2 2022 Earnings Call | Wed, Aug 03, 2022 · 8:30 AM ET | Replay |
| GlycoMimetics, Inc. (GLYC) Q1 2022 Earnings Call | Thu, Apr 28, 2022 · 8:30 AM ET | Replay |
| GlycoMimetics, Inc. (GLYC) Q4 2021 Earnings Call | Thu, Mar 03, 2022 · 8:30 AM ET | Replay |
All 13 calls
| Call | When | Status |
|---|---|---|
| GlycoMimetics, Inc. (GLYC) Q3 2021 Earnings Call | Tue, Nov 02, 2021 · 8:30 AM ET | Replay |
| GlycoMimetics, Inc. (GLYC) Q2 2021 Earnings Call | Thu, Aug 05, 2021 · 8:30 AM ET | Replay |
| GlycoMimetics, Inc. (GLYC) Q1 2021 Earnings Call | Mon, May 03, 2021 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −1.5% |
| Q2 2026 | Jul 30, 2026 · Before open | +1.7% |
| Q1 2026 | Apr 30, 2026 | −13.7% |
| Q4 2025 | Feb 26, 2026 · Before open | −1.1% |
| Q3 2025 | Nov 6, 2025 · Before open | +5.4% |
| Q2 2025 | Jul 31, 2025 · Before open | −1.4% |
| Q1 2025 | Jun 18, 2025 · After close | +2.6% |
| Q4 2024 | Feb 27, 2025 | −3.6% |
| Q3 2024 | Nov 29, 2024 | +6.5% |
| Q2 2024 | Aug 1, 2024 | −9.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 10, 2024 | −13.3% |
| Q4 2023 | Mar 27, 2024 | +5.3% |
| Q3 2023 | Nov 3, 2023 | +3.1% |
| Q2 2023 | Aug 2, 2023 | −1.8% |
| Q1 2023 | May 3, 2023 | +3.5% |
| Q4 2022 | Mar 29, 2023 | −10.7% |
| Q3 2022 | Nov 9, 2022 | +42.0% |
| Q2 2022 | Aug 3, 2022 | +10.4% |
| Q1 2022 | Apr 28, 2022 | −14.3% |
| Q4 2021 | Mar 3, 2022 | −21.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 56 slides | October 2026 |
| Investor Presentation (December 2025) | Investor deck | 53 slides | Dec 4, 2025 |
| Glycomimetics — Merger or Acquisition (April 2025) | Merger or acquisition | 27 slides | Apr 3, 2025 |
| Glycomimetics — Merger or Acquisition (February 2025) | Merger or acquisition | 27 slides | Feb 28, 2025 |
| Glycomimetics — Merger or Acquisition (January 2025) | Merger or acquisition | 27 slides | Jan 13, 2025 |
| Investor Presentation (November 2024) | Investor deck | 26 slides | Nov 18, 2024 |
| Investor Presentation (November 2024) | Investor deck | 25 slides | November 2024 |
Financings
| Raise | Date |
|---|---|
| Public offering of ordinary shares and pre-funded warrants Closed: US$143.7M in the latest tranche · US$14.5 a share · Jefferies +4 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), LifeSci Capital | Jul 30, 2026 |
| Private placement of ordinary shares and pre-funded warrants Announced: about US$185M · US$13.41 a share · Jefferies +5 Dealers: Jefferies, TD Cowen, Guggenheim Securities, Cantor, Wedbush & Co., Piper Sandler Buyers: Forbion; Fairmount; Vestal Point Capital; BVF Partners; ADAR1; Balyasny Asset Management; Venrock Healthcare Capital Partners Use of proceeds: Advance preclinical and clinical development of product candidates, working capital and general corporate purposes | Dec 4, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as GLYCOMIMETICS INC. Priced at US$8.00 a share on Jan 9, 2014.
- Price
- US$8.00 a share
- Shares offered
- 7,000,000 shares of common stock
- Offering size
- US$56 million
- Underwriters' option
- Up to 1,050,000 more shares
- Underwriters
- Jefferies, Barclays, Stifel, Canaccord Genuity · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 21, 2013 |
| Filed publicly | Oct 4, 2013 |
| Amended 4 times | Newest Jan 7, 2014 |
| Shares registered with an exchange | Nov 5, 2013 |
| Declared effective by the SEC | Jan 9, 2014 |
| Final prospectus, with the price | Jan 10, 2014 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jan 10, 2014 |
| EFFECT · Notice that a registration is effective | Jan 9, 2014 |
| CORRESP · Letter to the SEC | Jan 7, 2014 |
| S-1/A · Registration statement, amended | Jan 7, 2014 |
| CORRESP · Letter to the SEC | Jan 6, 2014 |
| S-1/A · Registration statement, amended | Dec 20, 2013 |
| CERTNAS · Nasdaq's certificate of listing | Nov 7, 2013 |
| FWP · Free writing prospectus | Nov 7, 2013 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 5, 2013 |
| CORRESP · Letter to the SEC | Nov 5, 2013 |
All 19 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Nov 5, 2013 |
| S-1/A · Registration statement, amended | Oct 31, 2013 |
| S-1/A · Registration statement, amended | Oct 28, 2013 |
| CORRESP · Letter to the SEC | Oct 23, 2013 |
| CORRESP · Letter to the SEC | Oct 18, 2013 |
| UPLOAD · Letter from the SEC | Oct 17, 2013 |
| S-1 · Registration statement | Oct 4, 2013 |
| UPLOAD · Letter from the SEC | Sep 19, 2013 |
| DRS · Draft registration statement | Aug 21, 2013 |
Open IPO · From the cover of the final prospectus (424B4) filed Jan 10, 2014
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.8M | 10.0K | 75.0K | 1.16M | 10.2M | 18.5K | ||||
| Cost of revenue | 84.0K | 35.2K | 153.3K | 1.03M | 951.6K | 899.3K | 275.1K | 263.5K | ||
| Gross profit | 10.8M | -35.2K | 10.0K | 75.0K | 1.16M | 10.2M | -899.3K | -275.1K | -263.5K | 18.5K |
| Research and development | 138.1M | 14.3M | 20.1M | 28.4M | 47.5M | 44.9M | 47.0M | 40.1M | 24.1M | 23.3M |
| Selling, general and administrative | 25.4M | 16.3M | 19.2M | 19.1M | 17.1M | 16.7M | 14.4M | 11.4M | 9.83M | 8.65M |
| Operating income | -152.6M | -40.0M | -39.3M | -47.4M | -63.4M | -51.5M | -61.4M | -51.5M | -33.9M | -31.9M |
| Depreciation and amortization | 84.0K | 35.2K | 153.3K | 207.1K | 264.6K | 270.8K | 279.2K | 275.1K | 263.5K | 190.5K |
| EBITDA | -152.5M | -40.0M | -39.1M | -47.2M | -63.2M | -51.2M | -61.1M | -51.2M | -33.7M | -31.7M |
| Interest expense | 2.19M | 852.0K | ||||||||
| Income before tax | -151.9M | -48.5M | -36.9M | -46.7M | -63.4M | -51.0M | -57.9M | -48.3M | -33.3M | -31.8M |
| Income tax | 2.00M | -3.78M | 3.23M | |||||||
| Net income | -153.9M | -37.9M | -36.9M | -46.7M | -63.4M | -51.0M | -57.9M | -48.3M | -33.3M | -31.8M |
| Earnings per share, basic | -5.59 | -0.59 | -0.58 | -0.89 | -1.23 | -1.12 | -1.34 | -1.18 | -1.13 | -1.50 |
| Earnings per share, diluted | -0.59 | -0.58 | -0.89 | -1.23 | -1.12 | -1.34 | -1.18 | -1.13 | -1.50 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 213.2M | 34.8M | 41.8M | 47.9M | 90.3M | 137.0M | 158.2M | 209.9M | 123.9M | 40.0M |
| Short-term investments | 10.6K | |||||||||
| Receivables | 18.0M | 0 | 175.8K | 144.0K | 1.35K | 2.15K | 186.0K | 413.1K | 102.0K | 268.7K |
| Inventory | -405 | 198.8K | ||||||||
| Current assets | 236.7M | 34.8M | 43.8M | 50.7M | 90.8M | 138.3M | 162.5M | 212.3M | 127.2M | 40.5M |
| Property, plant and equipment | 846.0K | 0 | 242.4K | 368.8K | 620.7K | 822.9K | 957.2K | 1.11M | 1.06M | |
| Total assets | 240.3M | 35.6M | 45.3M | 51.8M | 94.3M | 142.8M | 168.0M | 214.8M | 128.6M | 42.4M |
| Accounts payable | 10.00M | 329.3K | 868.1K | 970.2K | 2.11M | 2.09M | 1.44M | 2.66M | 2.65M | 1.57M |
| Current liabilities | 36.1M | 9.61M | 6.84M | 8.88M | 11.8M | 12.4M | 11.0M | 8.76M | 8.17M | 6.33M |
| Long-term debt | 37.5M | |||||||||
| Total debt | 1.64M | 37.5M | 808.4K | 918.6K | 1.92M | 2.82M | 3.62M | |||
| Total liabilities | 37.3M | 47.1M | 6.90M | 8.88M | 12.7M | 14.6M | 13.8M | 9.37M | 8.88M | 7.09M |
| Shareholders' equity | 203.0M | -15.5M | 38.4M | 42.9M | 81.6M | 128.2M | 154.2M | 205.5M | 119.7M | 35.3M |
| Shares outstanding | 27.6M | 1.02M | 64.4M | 54.4M | 52.3M | 49.0M | 43.5M | 43.2M | 34.4M | 23.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -71.5M | -31.1M | -34.9M | -46.5M | -57.5M | -39.2M | -52.0M | -43.3M | -29.8M | -29.7M |
| Capital spending | -919.0K | -9.97K | -21.4K | -84.2K | -14.9K | -68.5K | -144.9K | -125.6K | -294.1K | -704.2K |
| Free cash flow | -72.5M | -31.1M | -34.9M | -46.5M | -57.5M | -39.3M | -52.1M | -43.5M | -30.1M | -30.4M |
| Cash from investing | -72.9M | 20.0K | -21.4K | -84.2K | -14.9K | -68.5K | -144.9K | -125.6K | -294.1K | -704.2K |
| Cash from financing | 323.0M | 5.40K | 28.8M | 4.16M | 10.7M | 18.1M | 412.9K | 129.4M | 113.9M | 23.7M |
| Share buybacks | -177.0K | |||||||||
| Change in cash | 178.5M | -31.1M | -6.08M | -42.4M | -46.8M | -21.2M | -51.7M | 86.0M | 83.9M | -6.76M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 15, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 18, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Sep 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 16, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Aug 3, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Jul 30, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Jul 30, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Jul 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 20, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 15, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jul 15, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 14, 2026 | Results | SEC |
| 424B5 · Prospectus | Jul 14, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 13, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jul 1, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 22, 2026 | Offer document | SEC |
| 10-Q/A · Quarterly report, amended | Jun 22, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Apr 29, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 29, 2026 | Results | SEC |
| 10-Q · Quarterly report | Apr 29, 2026 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2026 | Meeting notice | SEC |
| 424B3 · Prospectus | Mar 17, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Mar 4, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Mar 2, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Feb 26, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jan 16, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jan 15, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 13, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 12, 2026 | Other filings | SEC |
| S-1 · Registration statement | Jan 7, 2026 | Offer document | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| S-4 POS | Dec 12, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 11, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 4, 2025 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Nov 6, 2025 | Offer document | SEC |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Nov 6, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 9, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 20, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 31, 2025 | Results | SEC |
| 10-Q · Quarterly report | Jul 31, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 15, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 8, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jun 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Jun 23, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jun 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 23, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 23, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 20, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 18, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Meeting outcome | SEC |
| 425 | May 30, 2025 | Other filings | SEC |
| 8-K · Current report | May 30, 2025 | Current report | SEC |
| 425 | May 29, 2025 | Other filings | SEC |
| SEC STAFF LETTER | May 16, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | May 15, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 424B3 · Prospectus | May 14, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 13, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 12, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | May 12, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 8, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 28, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Apr 28, 2025 | Offer document | SEC |
| 425 | Apr 28, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 28, 2025 | Material contract | SEC |
| 425 | Apr 28, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 22, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 4, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 4, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Apr 4, 2025 | Offer document | SEC |
| 425 | Apr 3, 2025 | Other filings | SEC |
| 425 | Apr 3, 2025 | Other filings | SEC |
| SEC STAFF LETTER | Mar 27, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 17, 2025 | Other filings | SEC |
| 425 | Feb 28, 2025 | Other filings | SEC |
| 425 | Feb 27, 2025 | Other filings | SEC |
| 425 | Feb 25, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 25, 2025 | Management or board change | SEC |
| S-4 · Registration statement | Feb 18, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 425 | Feb 14, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 14, 2025 | Material contract | SEC |
| 10-K · Annual report | Feb 13, 2025 | Annual report | SEC |
| 8-K · Current report | Jan 31, 2025 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Jan 13, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 8-K · Current report | Dec 26, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Nov 27, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Nov 7, 2024 | Meeting notice | SEC |
| 8-K · Current report | Nov 7, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Nov 6, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Nov 4, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Oct 29, 2024 | Meeting notice | SEC |
| 8-K · Current report | Oct 29, 2024 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 15, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 30, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 29, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jul 29, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2024 | Management or board change | SEC |
| 8-K · Current report | Jun 4, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| SC 13D/A · Big-stake notice, amended | May 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | May 6, 2024 | Results | SEC |
| 8-K · Current report | May 2, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
This page holds 200 of 682 filings. Open Filings
Cap table
Built by 6ix from Crescent Biopharma, Inc.’s releases · as of Sep 30, 2026
- Common shares
- 37,143,940
- Fully diluted
- 37,143,940
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 37,143,940 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 37,143,940 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| M James Barrett Other companies: Senseonics Holdings, Inc. (Director · Mar 17, 2016 – May 30, 2019 · Past); Kineta Inc. (Director · Feb 10, 2016 – Jun 15, 2018 · Past); Zosano Pharma Corp (Director · Jan 26, 2015 – Jan 30, 2015 · Past); Loxo Oncology Inc (Director · Jul 31, 2014 – Jul 28, 2015 · Past); Roka Bioscience Inc (Director · Jul 16, 2014 – Jun 28, 2017 · Past); Omthera Pharmaceuticals Inc (Director · Jul 18, 2013 – Jul 18, 2013 · Past); Supernus Pharmaceuticals, Inc. (Director · Apr 30, 2012 – Mar 16, 2016 · Past); Clovis Oncology Inc (Director · Nov 15, 2011 – Oct 11, 2018 · Past); Amicus Therapeutics Inc (Director · Jun 15, 2010 – Jun 12, 2014 · Past); Medimmune Inc (Director · Jun 30, 2006 – Jun 18, 2007 · Past); Pharmion Corp (Director · Jun 8, 2006 – Mar 7, 2008 · Past); Gyre Therapeutics, Inc. (Director · Apr 11, 2006 – Jun 7, 2012 · Past); Inhibitex Inc (Director · Feb 1, 2006 – Feb 13, 2012 · Past); Iomai Corp (Director · Jan 25, 2006 – Aug 4, 2008 · Past) | Director · Jan 9, 2014 – May 18, 2018 · Past |
| David Lubner Other companies: Braveheart Bio, Inc. (Director · Since at least Aug 5, 2026); CARGO Therapeutics, Inc. (Director · Since at least Nov 9, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Dyne Therapeutics, Inc. (Board Member · Since at least Jul 31, 2020); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Vor Biopharma Inc. (Director · Feb 4, 2021 – May 22, 2025 · Past); POINT Biopharma Global Inc (Director · Jul 7, 2020 – Dec 26, 2023 · Past); Nightstar Therapeutics PLC (Director · Jan 1, 2019 – Jun 7, 2019 · Past); Ra Pharmaceuticals Inc (Executive VP and CFO · Oct 25, 2016 – Apr 2, 2020 · Past); Tetraphase Pharmaceuticals Inc (SVP and CFO · Mar 19, 2013 – Aug 14, 2015 · Past) | Director · Since at least Jun 13, 2025 |
| Peter Harwin Other companies: Damora Therapeutics, Inc. (Chairman of the Board · Since at least Nov 10, 2025); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Cogent Biosciences, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Jul 6, 2020); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – Jan 22, 2024 · Past); Viridian Therapeutics, Inc. (Director · Oct 27, 2020 – Jun 26, 2024 · Past) | Chair of Board · Since at least Jun 13, 2025 |
| Tomas Kiselak Other companies: Cyclerion Therapeutics, Inc. (Chairman · Since at least Apr 1, 2026); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Viridian Therapeutics, Inc. (Director · Since at least Oct 27, 2020); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – Sep 27, 2024 · Past) | Director · Since at least Jun 13, 2025 |
| Mark Alan Goldberg Other companies: Blueprint Medicines Corp (Director · Since at least Jun 25, 2015); Audentes Therapeutics Inc (Director · Dec 11, 2017 – Jan 15, 2020 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 9, 2017 · Past); Aceragen Inc. (Director · Jan 7, 2014 – Jun 23, 2022 · Past); ImmunoGen Inc (Director · Nov 8, 2011 – Feb 12, 2024 · Past); Synageva BioPharma Corp (EVP, Medical & Reg. Strategy · Nov 2, 2011 – Sep 19, 2014 · Past) | Director · Jul 8, 2014 – May 1, 2024 · Past |
| Jonathan Violin Other companies: Cyclerion Therapeutics, Inc. (Chief Executive Officer · Since at least Apr 1, 2026); Dianthus Therapeutics, Inc. (Director · Since at least Sep 11, 2023); Astria Therapeutics Inc (Director · Since at least Jan 28, 2021); Viridian Therapeutics, Inc. (Chief Executive Officer, Director · Oct 27, 2020 – Feb 2, 2023 · Past); Trevena, Inc. (SVP-Scientific Affairs & IR · Jan 29, 2018 – Feb 28, 2018 · Past) | Director · Since at least Jun 13, 2025 |
| Scott Thomas Jackson Other companies: Mural Oncology plc (Director · Since at least Oct 31, 2023); Spero Therapeutics, Inc. (Director · Since at least Apr 16, 2020); MacroGenics, Inc. (Director · Since at least Jan 24, 2017); Celator Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 14, 2013 – Jul 12, 2016 · Past) | Director · Nov 27, 2018 – May 1, 2024 · Past |
| Timothy R. Pearson Other companies: Korro Bio, Inc. (Director · Since at least Nov 3, 2023); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past); Tesaro Inc (Exec. VP, CFO · May 27, 2014 – Jan 22, 2019 · Past); Catalyst Health Solutions Inc (EVP & Chief Financial Officer · Aug 22, 2011 – Jul 2, 2012 · Past) | Director · Mar 31, 2014 – May 1, 2024 · Past |
| Joshua Brumm Other companies: Dyne Therapeutics, Inc. (CEO & President, Director · Sep 16, 2020 – Mar 8, 2024 · Past); Kaleido Biosciences, Inc. (See Remarks · Feb 27, 2019 – Mar 4, 2019 · Past); Aravive Inc (COO and CFO · Nov 12, 2015 – Oct 19, 2017 · Past) | Chief Executive Officer · Since at least Jun 13, 2025 |
| Michael A Henos Other companies: Genoptix Inc (Director · Oct 29, 2007 – Feb 25, 2011 · Past); Atherogenics Inc (Director · Apr 26, 2006 – Oct 31, 2008 · Past); Inhibitex Inc (Director · Feb 1, 2006 – Feb 13, 2012 · Past) | Director · Jan 9, 2014 – Jul 15, 2015 · Past |
All 40 people
| Person | Seat |
|---|---|
| Patricia S Andrews Other companies: Geron Corporation (Director · Since at least Mar 25, 2026); Oncolytics Biotech Inc. (Director · Since at least Jan 1, 2026); Incyte Corporation (Chief Commercial Officer · Oct 21, 2008 – Jan 19, 2012 · Past) | Director · Jun 9, 2017 – May 1, 2024 · Past |
| Susan Moran Other companies: Tyra Biosciences, Inc. (Board member · Since at least May 7, 2024); BioAtla, Inc. (Director · Since at least Dec 15, 2020); RayzeBio, Inc. (CHIEF MEDICAL OFFICER · Sep 14, 2023 – Feb 26, 2024 · Past) | Director · Since at least Jun 13, 2025 |
| Harout Semerjian Other companies: Geron Corporation (President and Chief Executive Officer · Since at least Aug 7, 2025); Immunomedics Inc (President and CEO, Director · Apr 16, 2020 – Apr 16, 2020 · Past) | Chief Executive Officer, Director · Aug 6, 2021 – Jan 12, 2024 · Past |
| Helen M Thackray Other companies: ImmunoGen Inc (Director · Sep 22, 2021 – Feb 12, 2024 · Past); BioCryst Pharmaceuticals, Inc. (Chief R&D Officer · Sep 20, 2019 – Mar 31, 2025 · Past) | SVP Clinical Development, CMO · Jan 9, 2014 – Jan 20, 2021 · Past |
| Rachel King Other companies: Fulcrum Therapeutics, Inc. (Board Member · Since at least Nov 12, 2024); Novavax, Inc. (Director · Since at least Oct 31, 2018) | Director · Jan 7, 2016 – May 1, 2024 · Past |
| Richard William Scalzo Other companies: Dyne Therapeutics, Inc. (SVP, Head of Finance & Admin. · Sep 16, 2020 – Mar 11, 2025 · Past); Kaleido Biosciences, Inc. (Principal Accounting Officer · Oct 11, 2019 – Oct 11, 2019 · Past) | Chief Financial Officer · Since at least Jun 13, 2025 |
| Alexandra Balcom Other companies: Nuvalent, Inc. (Chief Financial Officer · Since at least Jul 28, 2021) | Director · Since at least Jun 13, 2025 |
| Chinmaya Rath Other companies: Geron Corporation (Senior Vice President, Chief Business Officer · Since Jul 13, 2026) | SVP and Chief Business Officer · Jan 12, 2024 – Jan 12, 2024 · Past |
| Daniel M. Junius Other companies: IDEXX Laboratories, Inc. (Director · Since at least Oct 30, 2023) | Director · Mar 29, 2024 – May 1, 2024 · Past |
| Jonathan McNeill Other companies: Dyne Therapeutics, Inc. (Chief Business Officer · Sep 16, 2020 – Aug 19, 2024 · Past) | President and Chief Operating Officer · Since at least Jun 13, 2025 |
| Ryan Lynch Other companies: Concert Pharmaceuticals Inc (PAO · Jun 15, 2017 – Aug 15, 2019 · Past) | Senior Vice President, Finance and Chief Accounting Officer · Since at least Jun 13, 2025 |
| Scott Koenig Other companies: MacroGenics, Inc. (Director · Since at least Feb 8, 2024) | Director · May 1, 2024 – May 1, 2024 · Past |
| Alex Balcom | Until Sep 18, 2026 · Past |
| Amy Reilly | Chief Communications Officer · Since at least Nov 3, 2026 |
| Barbara Bispham | General Counsel · Since at least Jun 13, 2025 |
| Brian M Hahn | SVP Finance, CFO · Jan 9, 2014 – Jun 18, 2024 · Past |
| Bruce S Johnson | SVP & Chief Commercial Officer · Jan 12, 2024 – Jan 12, 2024 · Past |
| Chris Doughty | Chief Business Officer · Since at least Nov 4, 2026 |
| Christopher Grant Doughty | Chief Business Officer · Since at least Jun 13, 2025 |
| Edwin Rock | Chief Medical Officer · Sep 2, 2022 – Jun 20, 2024 · Past |
| Ellie Im | Chief Medical Officer · Since at least Jun 22, 2026 |
| Eric Jay Feldman | Chief Medical Officer · Mar 1, 2021 – Mar 1, 2021 · Past |
| Jan Pinkas | Chief Scientific Officer · Since at least Jul 7, 2025 |
| Jenna Poist | Director, Corporate Communications · Since at least Nov 3, 2026 |
| John J Baldwin | Director · Jan 9, 2014 – Jun 29, 2016 · Past |
| John L Magnani | SVP of Research, CSO · Jan 9, 2014 – Nov 11, 2022 · Past |
| Rick Scalzo | Chief Financial Officer · Since at least Jul 31, 2025 |
| Tanya Sengupta | Executive Vice President, Chief of Strategy and Operations · Since at least Jul 31, 2025 |
| Wenjie Cheng | Senior Vice President, Technical Operations · Since at least Nov 4, 2026 |
| William M Gust | Director · Jan 9, 2014 – Jan 15, 2014 · Past |
Log in to ask 6ix AI your own questions about Crescent Biopharma, Inc.